| Phase 110 trials |
|
Phase 1
|
NCT07691450 |
Jan 2027 → Nov 2029 expected |
Nodal T-follicular helper cell lymphoma, follicular type, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma +6 |
City of Hope Medical Center |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT07036133 |
Dec 2022 → Feb 2027 expected |
cancer, hematopoietic and lymphoid cell neoplasm |
Acrotech Biopharma Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT03240211 |
Feb 2022 → Jul 2025 overdue |
primary cutaneous T-cell lymphoma |
University of Virginia |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02594267 |
Nov 2015 → Apr 2017 |
peripheral T-cell lymphoma, not otherwise specified |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01532011 |
Mar 2012 → Jun 2016 |
cancer of unknown primary site |
M.D. Anderson Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01206465 |
Sep 2010 → Feb 2015 |
cancer of unknown primary site |
University of Nebraska |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01114282 |
Aug 2010 → Feb 2014 |
plasma cell myeloma |
Stanford University |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01134341 |
Mar 2010 → Aug 2015 |
Sezary syndrome, mycosis fungoides, primary cutaneous anaplastic large cell lymphoma |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00554827 |
Aug 2007 → Jan 2012 |
primary cutaneous T-cell lymphoma |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00024245 |
May 2001 → Apr 2003 |
cancer of unknown primary site |
Memorial Sloan Kettering Cancer Center |
Completed
|
No outcome recorded
|
| Phase 1/28 trials |
|
Phase 1/2
|
NCT07225985 |
Apr 2026 → Sep 2030 expected |
T-cell non-Hodgkin lymphoma |
Fred Hutchinson Cancer Center |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03598998 |
Feb 2019 → May 2023 overdue |
Nodal T-follicular helper cell lymphoma, follicular type, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma +6 |
City of Hope Medical Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03161223 |
May 2018 → Feb 2023 overdue |
T-cell non-Hodgkin lymphoma |
University of Virginia |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT02013362 |
Mar 2014 → Dec 2015 |
peripheral T-cell lymphoma, not otherwise specified |
Mundipharma K.K. |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT01947140 |
Sep 2013 → Sep 2022 |
Hodgkins lymphoma, non-Hodgkin lymphoma, plasma cell myeloma |
Jennifer Amengual |
Terminated
|
No outcome recorded
Stop: Enrollment |
|
Phase 1/2
|
NCT01188876 |
Aug 2010 → Jul 2016 |
fallopian tube cancer, ovarian cancer, peritoneum cancer |
Massachusetts General Hospital |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT00481871 |
May 2007 → May 2011 |
Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, Waldenstrom macroglobulinemia |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT00052442 |
Aug 2002 → Mar 2009 |
lymphoma |
Spectrum Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
| Phase 210 trials · 1 missed |
|
Phase 2
|
NCT01336933 |
Jul 2011 → Dec 2016 |
anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, hepatosplenic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified |
University of Nebraska |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01178944 |
Sep 2010 → Jan 2015 |
esophageal adenocarcinoma, gastric adenocarcinoma, gastric squamous cell carcinoma, gastroesophageal junction adenocarcinoma +2 |
Roswell Park Cancer Institute |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01183065 |
Aug 2010 → Apr 2014 |
head and neck cancer |
Memorial Sloan Kettering Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01129206 |
Jul 2010 → Sep 2012 |
esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastroesophageal junction adenocarcinoma |
Ohio State University Comprehensive Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01118624 |
Mar 2010 → Apr 2012 |
breast carcinoma |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00998946 |
Sep 2009 → Aug 2012 |
B-cell non-Hodgkin lymphoma |
Spectrum Pharmaceuticals, Inc |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00722553 |
Jul 2008 → Apr 2011 |
transitional cell carcinoma, urinary bladder cancer |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00606502 |
Jan 2008 → Jun 2010 |
non-small cell lung carcinoma |
Spectrum Pharmaceuticals, Inc |
Completed
|
Missed primary
|
|
Phase 2
|
NCT00364923 |
Aug 2006 → Jan 2009 |
peripheral T-cell lymphoma, not otherwise specified |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00004238 |
Jul 1999 → Jun 2002 |
lung cancer |
Memorial Sloan Kettering Cancer Center |
Completed
|
No outcome recorded
|
| Phase 33 trials · 1 met primary |
|
Phase 3
|
NCT03355768 |
Sep → Nov 2018 |
peripheral T-cell lymphoma, not otherwise specified |
Jennifer Amengual |
Withdrawn
|
No outcome recorded
Stop: Business |
|
Phase 3
|
NCT03349333 |
Sep 2015 → Jul 2017 |
T-cell non-Hodgkin lymphoma, peripheral T-cell lymphoma, not otherwise specified |
Mundipharma (China) Pharmaceutical Co. Ltd |
Completed
|
Met primary
|
|
Phase 3
|
NCT01420679 |
Aug 2011 → Dec 2017 |
peripheral T-cell lymphoma, not otherwise specified |
Spectrum Pharmaceuticals, Inc |
Terminated
|
No outcome recorded
|
| Phase 41 trial |
|
Phase 4
|
NCT03150602 |
Aug 2016 → Dec 2020 |
lymphoid system deterioration, progressive, peripheral T-cell lymphoma, not otherwise specified |
Taiwan Mundipharma Pharmaceuticals Ltd. |
Unknown
|
No outcome recorded
|
| Phase not applicable1 trial |
| — |
NCT02551718 |
Sep 2015 → Jun 2020 |
acute leukemia of ambiguous lineage, acute lymphoblastic leukemia |
University of Washington |
Completed
|
No outcome recorded
|
| Comparator or background therapy8 trials |
|
Phase 1
|
NCT01820091 Background |
Apr 2013 → Apr 2015 |
non-small cell lung carcinoma |
Acrotech Biopharma Inc. |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT01789723 Background |
Mar 2013 → Mar 2015 |
non-Hodgkin lymphoma |
Acrotech Biopharma Inc. |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT04747236 Comparator |
Feb 2021 → Jun 2028 expected |
— |
University of Virginia |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT02106650 Background |
Jul 2014 → Oct 2018 |
peripheral T-cell lymphoma, not otherwise specified |
Acrotech Biopharma Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01626664 Comparator |
Jun 2012 → Aug 2015 |
adult T-cell leukemia/lymphoma |
Kyowa Kirin, Inc. |
Completed
|
No outcome recorded
|
|
Phase 3
|
NCT06561048 Comparator |
Oct 2024 → Nov 2027 expected |
Nodal T-follicular helper cell lymphoma, follicular type, anaplastic large cell lymphoma, angioimmunoblastic T-cell lymphoma, peripheral T-cell lymphoma, not otherwise specified |
Corvus Pharmaceuticals, Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT06072131 Comparator |
Oct 2023 → Jul 2030 expected |
peripheral T-cell lymphoma, not otherwise specified |
Acrotech Biopharma Inc. |
Recruiting
|
No outcome recorded
|
|
Phase 3
|
NCT01482962 Comparator |
Jun 2012 → Jun 2015 |
peripheral T-cell lymphoma, not otherwise specified |
Millennium Pharmaceuticals, Inc. |
Completed
|
Missed primary
|
|